. 2016 May 20;65(8):897–907. doi: 10.1007/s00262-016-1846-1

Table 2.

Treatment summary

Patient ID	Best overall response^b	Duration of best overall response (months)	Target lesion measurement (mm)^a			Site reactions
Patient ID	Best overall response^b	Duration of best overall response (months)	Baseline	4 wk. post-first injection	4 wk. post-second injection	First injection	Second injection
UW001	SD	8.2^c	33	31	31	S	E, S
UW002	PD		23	31	44	E, S	E, T
UW003	PD		20	19	24
UW004	PD		20	22	34
UW005	PD		22	22	32	P	S
UW006	SD	7.5^c	9	9	10		E
UW007	PD		9	14	22	E, S, P	E, S, T
UW008	PD		12	10	10		E, S
UW009	PD		10	15	15	S, T	S, T

There were no Grade 3 or higher treatment-related toxicities. Grade 1 and 2 toxicities were not prospectively collected

There was no clinical autoimmunity and no induction of pathological autoantibodies

PD progressive disease (per RECIST 1.0), SD stable disease (per RECIST 1.0), S swelling, E erythema, T tenderness, P pain

^aThe treated tumor lesions were the target lesions

^bPatients had a physical examination including evaluation of treated tumor lesions and repeat radiological imaging on Day 57 (±3 business days)

^cFrom Day 57 scan